[ad_1]
It was indicated that a single dose of the vaccine called “Ad26.COV2.S” responded equally positively at two doses and therefore would be easier to distribute.
It was noted that the effect of the vaccine, the clinical trials of which were conducted in approximately 1,000 adults by Moderna and Pfizer, in the elderly population is unclear at this stage.
In clinical trials, it was stated that while the immune response in young participants was around 64 percent, this rate remained at a low level of 36 percent in those 65 and older.
It was reported that J & J will test the vaccine on 60,000 people as the last stage, then request it from the US Food and Drug Administration for use and mass production.
Company officials announced that they expect the final phase, known as phase 3, to end by the end of the year or early 2021, and more details about the safety and effect of the vaccine will be shared when the studies are completed.
American drug maker Johnson & Johnson signed a $ 1 billion agreement with the United States government on August 5 for the production and delivery of 100 million doses of the Covid-19 vaccine.
By completing the 1st and 2nd stage clinical trials of the candidate vaccine called “Ad26.COV2.S” in the US and Belgium, the company aims to deliver more than 1 billion doses of vaccine next year if the 3rd stage is successful.
